FOSTER CITY, CA--(Marketwired - Aug 28, 2014) - SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), and its partner BTG plc (LSE: BTG), today announced that the China Food and Drug Administration has ...

BTG received Class III CE Mark certification for its DC Bead LUMI, a radiopaque drug-eluting bead for patients with hepatocellular carcinoma and malignant colorectal cancer metastasized to the liver, ...

DC Bead LUMI™provides real-timevisible, lasting confirmation of bead location duringand post-embolisation of hypervascular tumoursin the liver BTG plc (LSE: BTG), a global specialist healthcare ...

Eisai Co., Ltd. announced that it has received approval for a partial label change for the vascular embolization device DC Bead (specially controlled medical device) in Japan. The product is to be ...

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of the first patients in the EU with DC Bead LUMI™. Two patients were treated for hepatocellular carcinoma ...

BTG plc (LSE: BTG), a global specialist healthcare company, today announced the treatment of an Australian patient with DC Bead LUMI™, a next-generation development of the market leading DC Bead ®. DC ...

DC Bead Biocompatibles' proprietary drug eluting bead product developed for loading with the chemotherapeutic agent by the hospital. This product received CE Mark regulatory approval in June 2003 for ...

BTG plc, a global specialist healthcare company, has received Class III CE Mark certification for DC Bead LUMI the first commercially available radiopaque drug-eluting bead (DEB) in the EU which can ...

DC Bead LUMI' provides real-time visible, lasting confirmation of bead location during and post-embolisation of hypervascular tumours in the liver BTG plc (LSE: BTG), a global specialist healthcare ...